Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
The first treatment that relies on CRISPR is expected to receive U.S. approval next month. But it may cost millions of dollars per patient.
Source: NYT Health - Category: Consumer Health News Authors: Gina Kolata Tags: Sickle Cell Anemia Genetics and Heredity Genetic Engineering Blood Bone Marrow Hemoglobin Crispr (DNA) Drugs (Pharmaceuticals) CRISPR Therapeutics Vertex Pharmaceuticals Inc Source Type: news